DOI: 10.1055/s-00043364

Pharmaceutical Fronts

References

Li X, Yang C, Wan H. et al.
Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.

Eur J Pharm Sci 2017;
110: 51-61

Download Bibliographical Data

Access:
Access: